Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Austria-based biotechnology company Nabriva Therapeutics has appointed David Chiswell as its new CEO. Dr Chiswell succeeds George Golumbeski who has left the company.
Subscribe to our email newsletter
Dr Chiswell has been involved with Nabriva since its foundation, having served as chairman of the supervisory board for the past three years. He is currently chairman of Albireo Pharma, a position which he will retain.
Dr Chiswell founded and led Cambridge Antibody Technology (CAT) from 1990 until 2002. Since leaving CAT in 2002, he has served on the boards of a number of companies including: Arakis (sold to Sosei in 2005); nonexecutive chairman of Arrow Therapeutics (sold to Astra Zeneca in 2007); nonexecutive chairman of Daniolabs (sold to Vastox in 2007); and nonexecutive chairman of Sosei from 2004 to 2008.
Denise Knight, managing director of Nomura Phase4 Ventures (lead investor in Nabriva), now becomes chairman of the supervisory board of the company.